Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

1044516

USP

Atorvastatin Calcium

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Atorvastatin hemicalcium salt sesquihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C66H68CaF2N4O10 · 3H2O
CAS Number:
344423-98-9
Molecular Weight:
1209.39
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

atorvastatin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

InChI key

SHZPNDRIDUBNMH-NIJVSVLQSA-L

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Atorvastatin Calcium is a synthetic selective inhibitor of HMG-CoA reductase. It is insoluble in aqueous solution with pH below 4 and is freely soluble in methanol.

Application

Atorvastatin calcium USP reference standard intended for use in specified quality tests and assays.

Also used to prepare system suitability, standard, system suitability stock, identification, and standard stock solution for assay and impurity analysis according to the given below monographs of United States Pharmacopeia (USP):
  • Atorvastatin Calcium
  • Atorvastatin Calcium Tablets
  • Amlodipine and Atorvastatin Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Atorvastatin Related Compound C United States Pharmacopeia (USP) Reference Standard

USP

1044549

Atorvastatin Related Compound C

Development and validation of analytical methods for simultaneous estimation of atorvastatin calcium and ezetimibe in combined dosage form.
Rajamanickam, V., et al.
World Applied Sciences Journal, 9.12, 1424-1429 (2010)
Peter Norsk et al.
The Journal of physiology, 593(3), 573-584 (2015-03-17)
Weightlessness in space induces initially an increase in stroke volume and cardiac output, accompanied by unchanged or slightly reduced blood pressure.It is unclear whether these changes persist throughout months of flight.Here, we show that cardiac output and stroke volume increase
Xiao-ling Li et al.
International immunopharmacology, 23(2), 546-549 (2014-12-03)
This study aimed to investigate the efficacy of combined atorvastatin calcium and methylprednisolone for the treatment of multiple sclerosis relapse. Patients with multiple sclerosis (MS) at the relapse phase were randomized to receive either combined treatment of atorvastatin calcium and
Yuka Keyamura et al.
PloS one, 9(5), e96929-e96929 (2014-05-09)
Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of treated patients. Therefore, additional treatment is required for
Yanli Wang et al.
Histology and histopathology, 29(12), 1593-1600 (2014-08-01)
Statins are often prescribed for treatment of cardiovascular diseases, although there are still many patients who cannot be effectively treated by statins alone. Both probucol and cilostazol exhibit anti-atherogenic effects. In the current study, we attempted to investigate whether a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service